Dec. 2 at 2:25 PM
$NVAX Nuvaxovid Post-Marketing Safety (as of Dec 2025):
•Doses administered globally: >40M
•Overall profile: Very safe; consistent with clinical trials.
•Common side effects (>10%):
Injection-site pain, fatigue, headache, muscle pain (mild-moderate, resolve 1–3 days)
Serious adverse events: <0.1%
• Myocarditis/pericarditis: very rare (~0.5–2 per 100,000), mostly mild, far lower than mRNA vaccines
• Anaphylaxis: ~2–5 per million
• No confirmed deaths caused by the vaccine
• No signals for thrombosis, Guillain-Barré, or excess mortality
Special groups:
• Adolescents: similar to adults, slightly higher reactogenicity
•Regulatory status: Full/standard approval in EU & many countries; 2025–2026 JN.1 formula approved with same favorable safety profile.
•Bottom line: One of the safest COVID-19 vaccines in post-marketing experience, with the lowest myocarditis risk among approved options.
$NVAX #Biotech
$IBB $XBI
https://grok.com/share/c2hhcmQtMg_80ce3d07-9f9e-4e3a-a8ec-ce541563e1dc
